⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ARVN News
Arvinas, Inc
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
globenewswire.com
ARVN
Form 8-K
sec.gov
ARVN
Arvinas to Present at Jefferies Global Healthcare Conference
globenewswire.com
ARVN
Arvinas Employees Give Back During Company-wide Impact Day
globenewswire.com
ARVN
CapeHaven Completes First Close of Funding and Initiates Operations to Encourage Yale’s Biotech Spinouts
globenewswire.com
MRK
ARVN
Form 8-K
sec.gov
ARVN
RIGL
PFE
Form 8-K
sec.gov
ARVN
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com
ARVN
RIGL
PFE
Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)
globenewswire.com
ARVN
PFE
RIGL
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO